Aligos Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aligos Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2019 to Q2 2024.
  • Aligos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $2.06M, a 35.7% decline year-over-year.
  • Aligos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $14.7M, a 9.19% increase from 2021.
  • Aligos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $13.5M, a 352% increase from 2020.
  • Aligos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $2.98M, a 296% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $2.06M -$1.14M -35.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $2.65M -$1.02M -27.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q3 2023 $13.5M $3.21M -$282K -8.08% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $13.8M $3.2M -$797K -20% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $14.6M $3.66M -$122K -3.22% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $14.7M $3.42M -$239K -6.53% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-09
Q3 2022 $14.9M $3.49M -$101K -2.81% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $15M $3.99M +$546K +15.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $14.5M $3.79M +$1.03M +37.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $13.5M $3.66M +$2.36M +181% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $11.1M $3.59M +$2.58M +254% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $8.52M $3.45M +$3.12M +954% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $5.4M $2.76M +$2.43M +733% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $2.98M $1.3M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 $1.02M +$865K +573% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $327K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $331K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q3 2019 $151K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.